ES2538486T3 - Preparación de péptidos antigénicos contra el cáncer - Google Patents

Preparación de péptidos antigénicos contra el cáncer Download PDF

Info

Publication number
ES2538486T3
ES2538486T3 ES03795414.6T ES03795414T ES2538486T3 ES 2538486 T3 ES2538486 T3 ES 2538486T3 ES 03795414 T ES03795414 T ES 03795414T ES 2538486 T3 ES2538486 T3 ES 2538486T3
Authority
ES
Spain
Prior art keywords
peptide
preparation
antigenic peptides
against cancer
peptides against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03795414.6T
Other languages
English (en)
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Application granted granted Critical
Publication of ES2538486T3 publication Critical patent/ES2538486T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una emulsión de agua-en-aceite que comprende como ingrediente eficaz un péptido que tiene una secuencia de aminoácidos de Cys Tyr Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 3) que induce CTL que reconoce el péptido WT1 de tipo salvaje de una manera restringida por HLA-A24; en donde la emulsión está en una forma de dosificación unitaria que comprende de 0,1 a 100 mg del péptido.
ES03795414.6T 2002-09-12 2003-09-12 Preparación de péptidos antigénicos contra el cáncer Expired - Lifetime ES2538486T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002266876 2002-09-12
JP2002266876 2002-09-12
PCT/JP2003/011675 WO2004024175A1 (ja) 2002-09-12 2003-09-12 癌抗原ペプチド製剤

Publications (1)

Publication Number Publication Date
ES2538486T3 true ES2538486T3 (es) 2015-06-22

Family

ID=31986668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03795414.6T Expired - Lifetime ES2538486T3 (es) 2002-09-12 2003-09-12 Preparación de péptidos antigénicos contra el cáncer

Country Status (6)

Country Link
US (2) US7342092B2 (es)
EP (1) EP1550453B1 (es)
JP (2) JP4611022B2 (es)
AU (1) AU2003262094A1 (es)
ES (1) ES2538486T3 (es)
WO (1) WO2004024175A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
WO2005001117A1 (ja) 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
EP1844789B8 (en) * 2005-01-19 2014-10-08 Sumitomo Dainippon Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
EP1951281B1 (en) * 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
AU2007218649B2 (en) 2006-02-22 2013-01-10 International Institute Of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US9492548B2 (en) * 2012-12-14 2016-11-15 Intervet Inc. Emulsion containing a non-live medicinal substance
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
AU2019218397A1 (en) 2018-02-12 2020-10-01 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
CA3115240A1 (en) * 2018-10-05 2020-04-09 International Institute Of Cancer Immunology, Inc. Composition for preventing or treating benign tumor
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
CN111333711B (zh) * 2020-03-18 2020-10-09 北京鼎成肽源生物技术有限公司 一种肺癌抗原组合及其应用、细胞毒性t淋巴细胞

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6034235A (en) 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
KR19990076695A (ko) * 1995-12-22 1999-10-15 리차드 알. 이킨 시티딘 데아미나제 혹은 데옥시시티딘 데아미나제의 과발현과연관된 질병들을 치료하기 위한 활성제_및 방법
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
JP5230891B2 (ja) 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) * 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1

Also Published As

Publication number Publication date
JP4611022B2 (ja) 2011-01-12
US20070036808A1 (en) 2007-02-15
JPWO2004024175A1 (ja) 2006-01-05
EP1550453B1 (en) 2015-05-27
US20090263409A1 (en) 2009-10-22
AU2003262094A1 (en) 2004-04-30
WO2004024175A1 (ja) 2004-03-25
EP1550453A4 (en) 2009-06-24
US7342092B2 (en) 2008-03-11
JP2009275051A (ja) 2009-11-26
EP1550453A1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
ES2538486T3 (es) Preparación de péptidos antigénicos contra el cáncer
BR0208183A (pt) Peptìdeo modificado por wt1
BR9912410A (pt) Vacina para imunização de aves, e, processos para imunizar uma ave e para preparar uma vacina para imunizar uma ave
RU2013141920A (ru) Вакцинная композиция против злокачественной опухоли
PE20121393A1 (es) Analogo peptidico de oxintomodulina
BR0014386A (pt) Composição
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
RU2010110545A (ru) Cdh3-пептид и включающее его лекарственное средство
RU2013131089A (ru) Пептиды тем8 и содержащие их вакцины
MX382968B (es) Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
SA110310340B1 (ar) تركيبة لعلاج سرطان البروستاتا
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CO2021017664A2 (es) Péptidos
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
MY209484A (en) Cpg amphiphiles and uses thereof
RU2010154101A (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
CR7938A (es) Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico
BR112022004477A2 (pt) Imunoterapêutico para tratamento de câncer de próstata
RU2010126154A (ru) Эпитопные пептиды stat3
NO20084053L (no) Inhibering av tumorvekst
RU2014102941A (ru) Вакцинная композиция для введения через слизистую оболочку
ES2163631T3 (es) Un peptido mejorado, composicion inmunogenica y vacuna o preparacion medica, un procedimiento para inmunizar a los animales contra la hormona lhrh, analogos del peptido lhrh repetidos en tandem y su uso como vacuna.